Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Cheifetz

Showing results (101-110 of 264) with videos related to

Pageof 27
Sort By:
Journal of Cellular Physiology. Supplement|January 1, 1987
Multiple type-beta transforming growth factors and their receptorsJ Massagué, S Cheifetz, R A Ignotz, et al.
Digestive Diseases and Sciences|February 28, 2025
Delays in Utilizing Biological Therapy Is a Global Reality and May Lead to Negative Outcomes in Patients with Inflammatory Bowel DiseaseAnna H Owings, Sarah C Glover, Adam S Cheifetz, et al.
Annals of Gastroenterology|July 2, 2016
Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitisJoseph D Feuerstein, Mona Akbari, Elliot B Tapper, et al.
Journal of Clinical Gastroenterology|February 5, 2014
Characteristics of inflammatory bowel disease serology in patients with indeterminate colitisSiddharth P Sura, Awais Ahmed, Adam S Cheifetz, et al.
Journal of Cell Science. Supplement|January 1, 1990
Transforming growth factor-beta receptors and binding proteoglycansF T Boyd, S Cheifetz, J Andres, et al.
Therapeutic Advances in Chronic Disease|July 10, 2023
A primer on common supplements and dietary measures used by patients with inflammatory bowel diseaseHadi J Minhas, Konstantinos Papamichael, Adam S Cheifetz, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 2, 2017
Histological healing beyond endoscopic healing in ulcerative colitis: Shall we target the "ultra-deep" remission?Konstantinos H Katsanos, Konstantinos Papamichael, Dimitrios K Christodoulou, et al.
Digestive Diseases and Sciences|January 18, 2018
Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel DiseaseKonstantinos Papamichael, Ravy K Vajravelu, Mark T Osterman, et al.
Inflammatory Bowel Diseases|February 21, 2018
Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel DiseaseKonstantinos H Katsanos, Konstantinos Papamichael, Adam S Cheifetz, et al.
Journal of Cell Science|March 17, 2004
MyoD enhances BMP7-induced osteogenic differentiation of myogenic cell culturesM Komaki, A Asakura, M A Rudnicki, et al.
Pageof 27

Showing results (101-110 of 264) with videos related to

Sort By:
Pageof 27
Journal of Cellular Physiology. Supplement|January 1, 1987
Multiple type-beta transforming growth factors and their receptorsJ Massagué, S Cheifetz, R A Ignotz, et al.
Digestive Diseases and Sciences|February 28, 2025
Delays in Utilizing Biological Therapy Is a Global Reality and May Lead to Negative Outcomes in Patients with Inflammatory Bowel DiseaseAnna H Owings, Sarah C Glover, Adam S Cheifetz, et al.
Annals of Gastroenterology|July 2, 2016
Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitisJoseph D Feuerstein, Mona Akbari, Elliot B Tapper, et al.
Journal of Clinical Gastroenterology|February 5, 2014
Characteristics of inflammatory bowel disease serology in patients with indeterminate colitisSiddharth P Sura, Awais Ahmed, Adam S Cheifetz, et al.
Journal of Cell Science. Supplement|January 1, 1990
Transforming growth factor-beta receptors and binding proteoglycansF T Boyd, S Cheifetz, J Andres, et al.
Therapeutic Advances in Chronic Disease|July 10, 2023
A primer on common supplements and dietary measures used by patients with inflammatory bowel diseaseHadi J Minhas, Konstantinos Papamichael, Adam S Cheifetz, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 2, 2017
Histological healing beyond endoscopic healing in ulcerative colitis: Shall we target the "ultra-deep" remission?Konstantinos H Katsanos, Konstantinos Papamichael, Dimitrios K Christodoulou, et al.
Digestive Diseases and Sciences|January 18, 2018
Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel DiseaseKonstantinos Papamichael, Ravy K Vajravelu, Mark T Osterman, et al.
Inflammatory Bowel Diseases|February 21, 2018
Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel DiseaseKonstantinos H Katsanos, Konstantinos Papamichael, Adam S Cheifetz, et al.
Journal of Cell Science|March 17, 2004
MyoD enhances BMP7-induced osteogenic differentiation of myogenic cell culturesM Komaki, A Asakura, M A Rudnicki, et al.
Pageof 27